title: HU for acute treatment of sickle VOC?
abstract: In this issue of Blood, Almeida et al report immediate benefits of hydroxyurea (HU) acute administration in diminishing vaso-occlusive processes in sickle cell disease (SCD) mice.(1)
authors.affiliation: INSERM, France.
authors.forename: Wassim
authors.initials: W
authors.lastname: El Nemer
mesh_terms: D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000818:Animals; D000986:Antisickling Agents / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000378:metabolism*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D008297:Male; D011720:Pyrazoles / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D014652:Vascular Diseases / Q000188:drug therapy*
chemical_list: D000986:Antisickling Agents; C507056:BAY 73-6691; D011720:Pyrazoles; D011743:Pyrimidines; D006152:Cyclic GMP; D006918:Hydroxyurea